protocolSection identificationModule nctId: NCT06297252, orgStudyIdInfo id: RECHMPL23_0189, briefTitle: Prevalence of Psychiatric Disorders During Pregnancy at 2nd Trimester Ultrasound: a Feasibility Study in the General Population, acronym: GROUP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-09, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: University Hospital, Montpellier, class: OTHER, collaborators name: Beziers Hospital, descriptionModule briefSummary: Young women represent a population at risk of psychiatric disorders, the first signs of which often appear between the ages of 15 and 25. Psychiatric disorders are a major source of disability and healthcare costs.The perinatal period is an additional period of psychological vulnerability, during which women are at increased risk of developing or worsening psychiatric disorders. Unfortunately, psychiatric disorders seem to be largely under-diagnosed during this period, and therefore under-treated.The goal of this Prospective multicenter study is to determine the prevalence of the presence of at least one characterized psychiatric disorder, as defined by the use of the Mini International Neuropsychiatric Interview (MINI), in remission or not, during pregnancy, at the time of the second-trimester ultrasound (T2 ultrasound) based on a standardized clinical assessment.Participants will complete self-questionnaires and have a standardized psychiatric evaluation at T2 ultrasound and at 2 months postpartum., conditionsModule conditions: Pregnancy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: standardized clinical psychiatric evaluations, interventions name: self-administered psychiatric questionnaire assessments, interventions name: blood sampling, outcomesModule primaryOutcomes measure: To determine the prevalence of the presence of at least one characterized psychiatric disorder, in remission or not, during pregnancy, at the time of the second-trimester ultrasound (T2 ultrasound) based on a standardized clinical assessment., secondaryOutcomes measure: To determine the prevalence of each psychiatric disorder characterized during pregnancy at the time of the second-trimester ultrasound, based on a standardized clinical assessment., secondaryOutcomes measure: Determine comorbidity profiles across all pathologies, describing whether there are patient groups based on these profiles., secondaryOutcomes measure: Compare the prevalence of psychiatric disorders unknown to the obstetrics team with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound., secondaryOutcomes measure: Compare the prevalence of psychiatric disorders unknown to the patient with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound., secondaryOutcomes measure: Compare the prevalence of psychiatric disorders unknown to the general practitioner with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound., secondaryOutcomes measure: Assess patients' medication compliance using self-administered questionnaires (MARS)., secondaryOutcomes measure: Assess patients' treatment beliefs using self-administered questionnaires (BMQ)., secondaryOutcomes measure: Determine the sociodemographic, psychological, psychiatric, medical and obstetric factors, as well as those associated with access to care and the care pathway associated with known or unknown diagnoses during pregnancy., secondaryOutcomes measure: Determine the properties (sensitivity) of screening questionnaires (EPDS) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (specificity) of screening questionnaires (EPDS) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (positive predictive value) of screening questionnaires (EPDS) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (negative predictive value) of screening questionnaires (EPDS) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (sensitivity) of screening questionnaires ( MDQ) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (specificity) of screening questionnaires ( MDQ) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (positive predictive value) of screening questionnaires ( MDQ) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (negative predictive value) of screening questionnaires ( MDQ) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (sensitivity) of screening questionnaires (PCL-5) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (specificity) of screening questionnaires (PCL-5) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (positive predictive value) of screening questionnaires (PCL-5) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (negative predictive value) of screening questionnaires (PCL-5) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (sensitivity) of screening questionnaires (EDEQ) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (specificity) of screening questionnaires (EDEQ) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (positive predictive value) of screening questionnaires (EDEQ) for psychiatric disorders in this population., secondaryOutcomes measure: Determine the properties (negative predictive value) of screening questionnaires (EDEQ) for psychiatric disorders in this population., secondaryOutcomes measure: Compare mother-child bonding difficulties between patients with and without a psychiatric diagnosis at the time of the study, using scales (PAI)., secondaryOutcomes measure: Compare mother-child bonding difficulties between patients with and without a psychiatric diagnosis at the time of the study, using scales (MIBS)., secondaryOutcomes measure: Describe how the study will be carried out, either in person or by teleconsultation, and the reasons for this choice., secondaryOutcomes measure: Determine the prevalence of each psychiatric disorder at two months post-inclusion based on a standardized clinical assessment., eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False